1. Pink Sheet
  2. >>R&D

UK Launches Inquiry Into Its Clinical Trials Problems After Pharma Outcry

Ex-Health Minister To Report Back In Spring

 
• By Andrew McConaghie

Stung by criticism from the AstraZeneca and GSK CEOs, the UK government has launched an independent review into commercial clinical trials in the hopes of reversing a steep decline.

NHS
Delays to clinical trial initiation and poor recruitment levels are endangering the UK's status as a leading nation for commercial research. • Source: Shutterstock

The UK government hopes a new independent review can help find ways to halt a steep decline in the number of commercial clinical trials being conducted in the country.

The review, announced on 20 February, follows an outcry from the UK pharma industry association and critical comments from the CEOs of its two big pharma companies, AstraZeneca and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.